Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Common variable immunodeficiency: test indications and interpretations.

Catherine R Weiler1, Jennifer L Bankers-Fulbright

  • 1Department of Internal Medicine and Division of Allergic Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Mayo Clinic Proceedings
|September 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anaphylaxis: Advances in the Past 10 Years.

The journal of allergy and clinical immunology. In practice·2022
Same author

How good are mast cell mediators?

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2021
Same author

Accurate Diagnosis and Prognosis in Systemic Mastocytosis: The Role of Mutational Analysis.

The journal of allergy and clinical immunology. In practice·2020
Same author

The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.

The journal of allergy and clinical immunology. In practice·2020
Same author

Reply.

The journal of allergy and clinical immunology. In practice·2020
Same author

Omalizumab and Mast Cell Disorders: Are We There Yet?

The journal of allergy and clinical immunology. In practice·2019
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Common variable immunodeficiency (CVID) involves low antibody levels and varied symptoms. Genetic defects impact B-cell function, necessitating specific diagnostic tests for effective treatment.

Area of Science:

  • Immunology
  • Genetics
  • Clinical Medicine

Background:

  • Common variable immunodeficiency (CVID) is a heterogeneous primary immunodeficiency.
  • It is characterized by hypogammaglobulinemia and increased susceptibility to infections.
  • The genetic basis for CVID is complex, with multiple distinct genetic defects likely contributing to its varied phenotypes.

Purpose of the Study:

  • To review known genetic mutations associated with hypogammaglobulinemia.
  • To elucidate the impact of these gene products on B-cell development and function, particularly in CVID.
  • To outline diagnostic strategies and therapeutic guidelines for CVID.

Main Methods:

  • Literature review of genetic mutations and their effects on B-cell biology.
  • Analysis of phenotypic and genetic laboratory tests for CVID diagnosis.

Related Experiment Videos

  • Synthesis of current guidelines for test interpretation and treatment.

    • Main Results:

    • Several genetic mutations affecting B-cell development and function have been identified.
    • These mutations contribute to the diverse clinical presentations of CVID.
    • Specific diagnostic tests aid in identifying genetic causes and guiding therapy.

    Conclusions:

    • CVID likely results from multiple distinct genetic disorders.
    • Understanding the genetic underpinnings is crucial for accurate diagnosis and management.
    • Targeted genetic and phenotypic testing informs therapeutic interventions for CVID patients.